Providing affordable access to new treatment for leukaemia and lymphoma
More than 920 Australians each year will benefit from affordable access to a new medicine for leukaemia and lymphoma patients. Ibrutinib (sold as Imbruvica®) would normally cost $187,390 on average per course of treatment, putting it beyond the reach of most patients. This $466 million listing on the pharmaceutical benefits scheme will save patients hundreds…